Tibet Rhodiola Pharmaceutical Holding Class A Receivables

Tibet Rhodiola Pharmaceutical Holding Class A (600211.SS) currently reports a receivables of $940M as of June 2026. That compares with $970M in the prior-year period — down 3.2% year over year. Use the charts on this page to explore Tibet Rhodiola Pharmaceutical Holding Class A's receivables history and peer comparisons.

Tibet Rhodiola Pharmaceutical Holding Class A's receivables decreased from $970M to $940M — a 3.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tibet Rhodiola Pharmaceutical Holding Class A reported $940M in receivables as of June 2026. That compares with $970M in the prior-year period — down 3.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $940M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tibet Rhodiola Pharmaceutical Holding Class A, and consider following 600211.SS for alerts when major investors trade the stock.